HC Wainwright Lifts Earnings Estimates for Lyra Therapeutics

Lyra Therapeutics, Inc. (NASDAQ:LYRA) – Equities research analysts at HC Wainwright raised their Q3 2025 earnings per share estimates for Lyra Therapeutics in a note issued to investors on Thursday, August 14th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($6.52) for the quarter, up from their previous estimate of ($8.87). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Lyra Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Lyra Therapeutics’ Q4 2025 earnings at ($7.14) EPS, FY2026 earnings at ($7.02) EPS, FY2027 earnings at ($6.35) EPS, FY2028 earnings at ($4.01) EPS and FY2029 earnings at ($1.33) EPS.

Lyra Therapeutics (NASDAQ:LYRA) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($5.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.79) by $0.28. The company had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.18 million. Lyra Therapeutics had a negative return on equity of 404.56% and a negative net margin of 5,043.64%.

Separately, Wall Street Zen lowered Lyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 13th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $100.00.

Lyra Therapeutics Stock Performance

NASDAQ:LYRA opened at $7.09 on Monday. The firm has a market capitalization of $11.66 million, a price-to-earnings ratio of -0.24 and a beta of 0.16. Lyra Therapeutics has a 52-week low of $3.81 and a 52-week high of $37.50. The stock has a fifty day moving average of $8.83 and a 200 day moving average of $8.36.

Institutional Investors Weigh In On Lyra Therapeutics

Several hedge funds have recently added to or reduced their stakes in LYRA. JPMorgan Chase & Co. lifted its stake in Lyra Therapeutics by 161.8% during the fourth quarter. JPMorgan Chase & Co. now owns 156,442 shares of the company’s stock worth $32,000 after purchasing an additional 96,681 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Lyra Therapeutics during the fourth quarter worth about $51,000. Northern Trust Corp lifted its stake in Lyra Therapeutics by 56.2% during the fourth quarter. Northern Trust Corp now owns 286,310 shares of the company’s stock worth $59,000 after purchasing an additional 103,026 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Lyra Therapeutics by 15.3% in the fourth quarter. Geode Capital Management LLC now owns 885,966 shares of the company’s stock worth $183,000 after buying an additional 117,578 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Lyra Therapeutics by 33.7% in the 2nd quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after acquiring an additional 7,190 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

About Lyra Therapeutics

Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.